GC Green Cross MS Invests in Swiss Blood Purification Technology Company

[Asia Economy, Reporter: Cho Hyun] GC Green Cross MS announced on July 23 that it has invested in the Swiss biotech startup Hemotune to expand its business. The size of the investment remains undisclosed as per mutual agreement between the two companies.

Founded in 2017, Hemotune possesses blood purification technology utilizing magnetic nanoparticles. The principle involves selectively removing toxic substances such as viruses, bacteria, and cytokines (immune substances) from the blood using magnetic nanoparticles, and then reinfusing the purified blood back into the body.

GC Green Cross MS will be responsible for sales of this technology in the Asian market and plans to collaborate on the production of magnetic nanoparticles and blood purification devices in the future.

Currently, Hemotune is conducting research and development to treat COVID-19 using its blood purification technology, funded by the European Institute of Innovation and Technology (EIT Health).

GC Green Cross MS explained that this technology could be applied not only to infectious diseases but also to a wide range of medical fields, including cancer, organ transplantation, and immune disorders.

An Eunok, CEO of GC Green Cross MS, stated, "Hemotune's blood purification technology is recognized as an innovative technology for removing viruses and bacteria," adding, "We plan to expand into new business areas by linking this technology to our blood dialysis business."

This content was produced with the assistance of AI translation services.